Literature DB >> 30477806

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.

Ichidai Tanaka1, Masahiro Morise2, Yuta Kodama2, Akira Matsui2, Naoya Ozawa2, Sachiko Ozone2, Daiki Goto2, Ayako Miyazawa2, Tetsunari Hase2, Naozumi Hashimoto2, Mitsuo Sato3, Yoshinori Hasegawa2.   

Abstract

Entities:  

Year:  2018        PMID： 30477806     DOI： 10.1016/j.lungcan.2018.11.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  6 in total

1.  Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.

Authors:  Pierre Tankere; Romain Boidot; Philippe Bonniaud; Ayoube Zouak; Pascal Foucher; Alice Milliere; Aurélie Bertaut; Laure Favier; Aurélie Lagrange; François Ghiringhelli; Courèche Guillaume Kaderbhai; Cléa Fraisse
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.

Authors:  Soei Gen; Ichidai Tanaka; Masahiro Morise; Junji Koyama; Yuta Kodama; Akira Matsui; Ayako Miyazawa; Tetsunari Hase; Yoshitaka Hibino; Toshihiko Yokoyama; Tomoki Kimura; Norio Yoshida; Mitsuo Sato; Naozumi Hashimoto
Journal:  BMC Cancer       Date:  2022-06-14       Impact factor: 4.638

3.  Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR exon 20 and exon 21: a case report.

Authors:  Xiaojun Bi; Pengyu Song; Chengye Wang; Xuefei Zhang; Changhong Liu
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

4.  Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation.

Authors:  Félix Blanc-Durand; Marie Florescu; Mustapha Tehfe; Bertrand Routy; Raafat Alameddine; Danh Tran-Thanh; Normand Blais
Journal:  Curr Oncol       Date:  2021-02-26       Impact factor: 3.677

5.  A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.

Authors:  Hai-Yan Tu; Jifeng Feng; Meiqi Shi; Jun Zhao; Yuyan Wang; Jianhua Chang; Jialei Wang; Ying Cheng; Jing Zhu; Eng-Huat Tan; Kai Li; Yiping Zhang; Victor Lee; Cheng-Ta Yang; Wu-Chou Su; David Chi-Leung Lam; B J Srinivasa; Senthil Rajappa; Ching-Liang Ho; Kwok Chi Lam; Yi Hu; Shailesh Arjun Bondarde; Xiaoqing Liu; Yahui Tian; Zhiyi Xue; Agnieszka Cseh; Dennis Chin-Lun Huang; Caicun Zhou; Yi-Long Wu
Journal:  Target Oncol       Date:  2022-01-12       Impact factor: 4.493

6.  Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea.

Authors:  Sung Yong Lee; Chang-Min Choi; Yoon Soo Chang; Kye Young Lee; Seung Joon Kim; Sei Hoon Yang; Jeong Seon Ryu; Jeong Eun Lee; Shin Yup Lee; Ji Young Park; Young-Chul Kim; In-Jae Oh; Chi Young Jung; Sang Hoon Lee; Seong Hoon Yoon; Juwhan Choi; Tae Won Jang
Journal:  Transl Lung Cancer Res       Date:  2021-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.